KREBS BIOCHEMICALS & IND Latest Share Price (KREBSBIO)
TODAY IN ONE LINE
KREBSBIO rose 2.7% on average volume, outperforming Nifty's 0.1% move.
With a market cap of ₹120.74 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
KREBS BIOCHEMICALS & IND flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 70.6% YoY
- ●Promoter SellingPromoter holding decreased by 72.74% QoQ
Latest KREBS BIOCHEMICALS & IND News
What changed recently?
Recent events, corporate actions, and announcements.
KREBS BIOCHEMICALS & IND valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for KREBS BIOCHEMICALS & IND, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
KREBS BIOCHEMICALS & IND technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for KREBS BIOCHEMICALS & IND — derived from the latest tape, not yesterday's close.
KREBS BIOCHEMICALS & IND last traded at ₹55.95 with an intraday range of ₹54.45–₹56.5 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹55.95| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 60.92 | +4.97 | +8.88% |
| R3 | 58.87 | +2.92 | +5.21% |
| R2 | 57.68 | +1.73 | +3.10% |
| R1 | 56.82 | +0.87 | +1.55% |
| PIVOT | 55.63 | -0.32 | -0.57% |
| CURRENT | 55.95 | — | — |
| S1 | 54.77 | -1.18 | -2.11% |
| S2 | 53.58 | -2.37 | -4.23% |
| S3 | 52.72 | -3.23 | -5.78% |
| S4 | 50.67 | -5.28 | -9.44% |
KREBSBIO is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹56.49–₹56.5
Trading Inside opening range
KREBS BIOCHEMICALS & IND financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for KREBS BIOCHEMICALS & IND — consolidated or standalone — with margins, YoY growth and key ratios inline.
KREBS BIOCHEMICALS & IND reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹120.74 Cr. and reported EPS of ₹-1.15.
KREBS BIOCHEMICALS & IND segment analysis : revenue and profit mix.
Disclosed business segments at KREBS BIOCHEMICALS & IND with their share of revenue and profit, switchable between consolidated and standalone reporting.
KREBS BIOCHEMICALS & IND discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for KREBS BIOCHEMICALS & IND.
Our AI distills the core fundamental drivers supporting KREBS BIOCHEMICALS & IND, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
KREBS BIOCHEMICALS & IND's investment case rests on 9 positive markers and 11 flagged concerns drawn from the latest reported filings.
What you're getting.
Diverse API portfolio spanning cholesterol, hypertension, anti-obesity, anti-inflammatory sectors
Contract manufacturing services provide revenue diversification beyond proprietary APIs
Established operational presence since 1991 with infrastructure in Visakhapatnam
TTM revenue growth 11.6% YoY demonstrates near-term demand resilience
Pharmaceutical sector growth trends could drive demand for API products
Key Risks.
Operating margin severely negative at -41.49% quarterly, indicating acute profitability erosion
ROCE deeply negative at -15.89%, reflecting poor capital deployment efficiency
Total equity negative at -₹1,608 Cr with debt of ₹225 Cr, raising solvency concerns
Operating cash flow negative at -₹16.76 Cr, limiting debt servicing capacity
EPS deeply negative at -₹1.15 with zero dividend yield, no shareholder returns
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
KREBS BIOCHEMICALS & IND peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — KREBS BIOCHEMICALS & IND is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
KREBS BIOCHEMICALS & IND chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for KREBS BIOCHEMICALS & IND — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
KREBS BIOCHEMICALS & IND delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for KREBS BIOCHEMICALS & IND over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in KREBS BIOCHEMICALS & IND stood at 84.9% of traded volume, against a 20-day average of 81.8%.
KREBS BIOCHEMICALS & IND announcements: results, concalls, ratings, M&A.
Filings KREBS BIOCHEMICALS & IND sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
KREBS BIOCHEMICALS & IND files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 42 documents below.
Shareholders meeting
Krebs Biochemicals and Industries Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026
Copy of Newspaper Publication
Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication w.r.t. prior intimation of 34th AGM of the…
Copy of Newspaper Publication
Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication
Outcome of Board Meeting
Krebs Biochemicals and Industries Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Krebs Biochemicals and Industries Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
KREBS BIOCHEMICALS & IND dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue KREBS BIOCHEMICALS & IND has declared, sequenced by announce and record date.
KREBS BIOCHEMICALS & IND corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About KREBS BIOCHEMICALS & IND: business, sector, key facts.
What KREBS BIOCHEMICALS & IND does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
KREBS BIOCHEMICALS & IND operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: KREBSBIO, BSE: 524518.
Krebs Biochemicals & Industries Limited (KrebsBIO) is an Indian company primarily focused on the manufacturing and sale of Active Pharmaceutical Ingredients (APIs). Their core business revolves around developing and producing key components used in various pharmaceutical formulations. The company's expertise lies in utilizing biotechnological processes to create these APIs, extending their reach beyond medicine into agricultural and industrial applications.
A significant portion of KrebsBIO's product portfolio consists of APIs used in cholesterol management and steroid synthesis. Specifically, they manufacture androstenedione, lovastatin, and simvastatin, all vital components in medications aimed at lowering cholesterol levels. These products highlight their capabilities in producing complex molecules with therapeutic value.
Beyond cholesterol-focused APIs, KrebsBIO develops and offers a diverse range of other pharmaceutical ingredients. This includes amlodipine (used in anti-hypertension medications), cetirizine (an anti-histamine), orlistat (an anti-obesity drug), serratiopeptidase (an anti-inflammatory agent), telmisartan (another anti-hypertension medication), and phenylephrine (commonly found in cold and cough remedies). This broad spectrum showcases their versatility and ability to cater to various therapeutic areas.
In addition to its own product development and manufacturing, KrebsBIO actively participates in contract manufacturing services. This allows them to provide their manufacturing expertise to larger pharmaceutical and multinational companies, offering a valuable outsourcing solution for the production of APIs. This aspect diversifies their revenue streams and strengthens their position within the pharmaceutical industry.
Established in 1991 and headquartered in Visakhapatnam, India, KrebsBIO has a long history of contributing to the pharmaceutical sector. Their combination of in-house API production, biotechnological process development, and contract manufacturing capabilities positions them as a significant player in the Indian pharmaceutical landscape and a potential supplier to global markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about KREBS BIOCHEMICALS & IND (KREBSBIO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of KREBS BIOCHEMICALS & IND (KREBSBIO)?
The current share price of KREBS BIOCHEMICALS & IND (KREBSBIO) is ₹55.95. Today, the stock has gained by ₹1.45 (2.66%), trading in a range of ₹54.45 to ₹56.50. The stock opened at ₹56.50 with a trading volume of 5,830 shares.
02Is KREBS BIOCHEMICALS & IND stock a good investment for long-term?
KREBS BIOCHEMICALS & IND can be considered for long-term investment based on several factors. The company has a market capitalization of ₹120.74 Cr., P/E ratio of 0, ROE of 0%, and ROCE of -15.89%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of KREBS BIOCHEMICALS & IND stock?
The 52-week high price of KREBS BIOCHEMICALS & IND (KREBSBIO) is ₹82.49, while the 52-week low is ₹38.33. Currently trading at ₹55.95, the stock is 45.97% above its 52-week low and 32.17% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy KREBS BIOCHEMICALS & IND stock at the current price?
Whether to buy KREBS BIOCHEMICALS & IND stock at ₹55.95 depends on multiple factors. The stock is currently trading with a P/E ratio of 0 and P/B ratio of 0. Today's performance shows a gain of 2.66%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of KREBS BIOCHEMICALS & IND and when is the next dividend?
KREBS BIOCHEMICALS & IND offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹55.95, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06How is KREBS BIOCHEMICALS & IND stock performing today in the market?
KREBS BIOCHEMICALS & IND stock opened at ₹56.50 and is currently trading at ₹55.95, showing a gain of ₹1.45 (2.66%). The intraday high is ₹56.50 and low is ₹54.45. The trading volume stands at 5,830 shares, indicating moderate market participation today.
07What is the P/E ratio of KREBS BIOCHEMICALS & IND and what does it indicate?
KREBS BIOCHEMICALS & IND has a Price-to-Earnings (P/E) ratio of 0, which means investors are willing to pay 0.00 for every ₹1 of earnings. With an EPS of ₹-1.15, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
08What is the market capitalization of KREBS BIOCHEMICALS & IND?
KREBS BIOCHEMICALS & IND has a market capitalization of ₹120.74 Cr., making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹55.95) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
The data, ratios and commentary about KREBS BIOCHEMICALS & IND (KREBSBIO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.